ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com



Ò½ÏßÒ©ÎÅ1. 5ÔÂ5ÈÕ£¬£¬£¬£¬£¬¹ðÁÖÈý½ðͨ¸æ£¬£¬£¬£¬£¬¿ËÈÕ£¬£¬£¬£¬£¬¹«Ë¾¿Ø¹ÉË﹫˾±¦´¬ÉúÎïÒ½Ò©¿Æ¼¼ÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄBC006µ¥¿¹×¢ÉäÒºµÄÁÙ´²ÊÔÑéÅú¼þ£¬£¬£¬£¬£¬Ô޳ɸÃÒ©Æ·¿ªÕ¹ÓÃÓÚÌØ·¢ÐÔ·ÎÏËά»¯Ë³Ó¦Ö¢µÄÁÙ´²ÊÔÑé¡£¡£¡£
2. 4ÔÂ29ÈÕ£¬£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬ÉϺ£¸´ÐÇÒ½Ò©¹¤ÒµÉú³¤ÓÐÏÞ¹«Ë¾É걨µÄFCN-159ƬÄâÄÉÈëÍ»ÆÆÐÔÖÎÁÆÆ·ÖÖ£¬£¬£¬£¬£¬Õë¶Ô˳Ӧ֢Ϊ¶ùͯÀʸñººË¹×é֯ϸ°ûÔöÉúÖ¢£¨LCH£©¡£¡£¡£
3. ¿ËÈÕ£¬£¬£¬£¬£¬ÓÉÖйú¿ÆÑ§ÔºÉϺ£Ò©ÎïÑо¿ËùºÍÑĮ̀ÐÂÒ©´´Ôìɽ¶«Ê¡ÊµÑéÊÒÁªºÏÉ걨µÄ»¯Ò©1ÀàÐÂÒ©X-L177½ºÄÒ£¬£¬£¬£¬£¬ÀֳɻñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö½ÒÏþµÄÁÙ´²ÊÔÑé֪ͨÊ飬£¬£¬£¬£¬»ñ×¼¿ªÕ¹ÖÎÁÆËèϵ¶ñÐÔÖ×ÁöµÄIÆÚÁÙ´²ÊÔÑé¡£¡£¡£
1. ŵ»ªÍýÏëÒÔ8ÒÚÃÀÔªÔ¤¸¶¿îÊÕ¹ºÎ»ÓÚÊ¥µØÑǸçµÄÉúÎï¿Æ¼¼¹«Ë¾Regulus Therapeutics£¬£¬£¬£¬£¬¸Ã¹«Ë¾×¨×¢ÓÚmicroRNAÒ©ÎïµÄÑз¢¡£¡£¡£´Ë´ÎÊÕ¹ºµÄ½¹µã×ʲúÊÇfarabursen£¬£¬£¬£¬£¬ÕâÊÇÒ»ÖÖÕë¶ÔÓëÉö²¡Ïà¹ØµÄmiR-17µÄºòѡҩÎ£¬£¬£¬£¬¸ÕÍê³ÉÕë¶Ô¶àÄÒÉö²¡»¼ÕßµÄ1bÆÚÁÙ´²ÊÔÑé¡£¡£¡£
2. ¿ËÈÕ£¬£¬£¬£¬£¬ÖÇкÆÕý£¨ÉϺ££©Ò½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾Ðû²¼Íê³É½ü 2 ÒÚÔªÈËÃñ±ÒÈÚ×Ê£¬£¬£¬£¬£¬±¾ÂÖÈÚ×ÊÓÉÒÚÔª A ÂÖÈÚ×ʺÍÀϹɶ«Ôö×浀 Pre-A+ ÂÖÅäºÏ×é³É¡£¡£¡£ÐÂΟåÖ¸³ö£¬£¬£¬£¬£¬±¾ÂÖ×ʽð½«ÖصãÍÆ½øº£ÄÚÊ׸öÒìÌåͨÓÃÐÍÔÙÉúÒȵº¹ÜÏßÁÙ´² I/II ÆÚÊÔÑ飬£¬£¬£¬£¬¼ÓËÙÍØÕ¹ÑÇÖÞÕ½ÂԽṹ£¬£¬£¬£¬£¬¿ªÍØÌÇÄò²¡ºÍ¸Î²¡ÖÎÁƵÄйÜÏß¡£¡£¡£
1. 4ÔÂ25ÈÕ£¬£¬£¬£¬£¬É½¶«´óѧÆë³ҽԺÕųÎ/ÕÅÃͽÌÊÚÍŶÓÔÚ Signal Transduction and Targeted Therapy ÔÓÖ¾ÉϽÒÏþÁËÌâΪ¡¸STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation¡¹µÄÑо¿ÂÛÎÄ¡£¡£¡£¸ÃÑо¿Ê×´ÎÃ÷È·ÁËÒ»ÖÖеÄ×ÔÊÉÒÀÀµÐÔÌúéæÃü»úÖÆ£¬£¬£¬£¬£¬ÆÊÎöÁËȱÑõ»òȱѪÔÙ¹à×¢ÓÕµ¼µÄ STING ×ÔÊɻᵼÖ GPX4 ½µ½â£¬£¬£¬£¬£¬ÎªÈ±ÑªÐÔÐÄÔಡµÄÖÎÁÆÌṩÁËеIJßÂԺ͸ÉÔ¤°Ðµã¡£¡£¡£
[1]Wang, X., Chen, T., Chen, S. et al. STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation. Sig Transduct Target Ther 10, 136 (2025). https://doi.org/10.1038/s41392-025-02216-9
Ïà¹ØÐÂÎÅ